

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Rodman David Malcom</u>  (Last) (First) (Middle) <u>150 N. RADNOR CHESTER ROAD, SUITE F200</u>  (Street) <u>RADNOR PA 19087</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Mineralys Therapeutics, Inc. [ MLYS ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____  <b>Chief Medical Officer</b>
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/10/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/10/2023		M		74,625	A	\$0.54	74,625	D	
Common Stock	08/10/2023		S		74,625	D	\$13.16 <sup>(1)</sup>	0	D	
Common Stock	08/11/2023		M		80,909	A	\$0.54	80,909	D	
Common Stock	08/11/2023		S		80,909	D	\$12.81 <sup>(2)</sup>	0	D	
Common Stock	08/11/2023		M		76,182	A	\$1.08	76,182	D	
Common Stock	08/11/2023		S		76,182	D	\$12.81 <sup>(2)</sup>	0	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option	\$0.54 <sup>(3)</sup>	08/10/2023		M			74,625	(4)	03/11/2031	Common Stock	74,625	\$0	166,202	D	
Stock Option	\$0.54 <sup>(3)</sup>	08/11/2023		M			80,909	(4)	03/11/2031	Common Stock	80,909	\$0	85,293	D	
Stock Option	\$1.08 <sup>(5)</sup>	08/11/2023		M			76,182	(6)	07/11/2031	Common Stock	76,182	\$0	228,548	D	

**Explanation of Responses:**

- The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from \$13.00 to \$13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from \$12.39 to \$13.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- Due to a rounding error, the exercise price for this stock option was originally reported as \$0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
- The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
- Due to a rounding error, the exercise price for this stock option was originally reported as \$1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
- The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

**Remarks:**

/s/ Adam Levy, Attorney-in-fact 08/11/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

